Holen Sie sich die Stockscreener-App
0.8226
3.22%
-0.0274
Metavia Inc Aktie (MTVA) Neueste Nachrichten
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PR Newswire
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider
MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan
Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX
MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World
MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research
Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz
MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com
MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Smart Shirt Might Predict Heart Problems - WFMZ.com
MetaVia reports positive obesity drug trial results - Investing.com Australia
MetaVia Announces Positive Phase 1 Trial Results - TipRanks
Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com
MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks
MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726 - StreetInsider
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss Without TitrationGame-Changing Trial Results - Stock Titan
Home-Delivered Medical Meals Could Prevent Millions Of Hospitalizations A Year - WFMZ.com
SCHD ETF News, 4/14/2025 - The Globe and Mail
MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World
Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks
MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus
MetaVia Inc. (MTVA) reports earnings - Quartz
Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV
Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire
Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV
New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV
Ears Ringing? Diet Changes Might Reduce Risk Of Tinnitus - 69News WFMZ-TV
Combination Therapy Recommended For Migraines - 69News WFMZ-TV
Dance Soothes Agitation In Alzheimer's Patients - 69News WFMZ-TV
MetaVia (MTVA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Stock market today: Wall Street rises ahead of Fed announcement - 69News WFMZ-TV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):